Get the Stockscreener App
2.985
2.77%
-0.085
Actuate Therapeutics Inc stock is traded at $2.985, with a volume of 38,501.
It is down -2.77% in the last 24 hours and up +42.14% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$3.07
Open:
$3.08
24h Volume:
38,501
Relative Volume:
0.33
Market Cap:
$69.97M
Revenue:
-
Net Income/Loss:
$-22.23M
P/E Ratio:
-2.7757
EPS:
-1.0754
Net Cash Flow:
$-19.21M
1W Performance:
+3.65%
1M Performance:
+42.14%
6M Performance:
-52.09%
1Y Performance:
-67.59%
1-Day Range:
$2.91
$3.08
1-Week Range:
$2.7612
$3.1299
52-Week Range:
$1.58
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
2.951 | 72.79M | 0 | -22.23M | -19.21M | -1.0754 |
VRTX
Vertex Pharmaceuticals Inc
|
428.25 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.03 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.18 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.00 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | B. Riley Securities | Buy |
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors - GlobeNewswire
Actuate Therapeutics (ACTU) price target decreased by 17.00% to 21.16 - MSN
Short Interest in Actuate Therapeutics, Inc. (NASDAQ:ACTU) Grows By 40.1% - MarketBeat
Actuate Therapeutics announces public offering of common stock - MSN
Why did Actuate Therapeutics (ACTU) stock jump over 14% after hours? - MSN
Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - whbl.com
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $15 - Moomoo
HC Wainwright Reiterates "Buy" Rating for Actuate Therapeutics (NASDAQ:ACTU) - MarketBeat
H.C. Wainwright reiterates Buy on Actuate Therapeutics stock By Investing.com - Investing.com Canada
Actuate Therapeutics Inc - Reuters
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours? - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
HC Wainwright Issues Optimistic Estimate for ACTU Earnings - National Today
B.Riley cuts Actuate Therapeutics stock price target on revenue timing - Investing.com
Actuate Therapeutics Reports Significant Survival Improvement in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial doubled one-year survival in study - Stock Titan
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewswire
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial - Nature
ACTU Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
H.C. Wainwright lowers Actuate Therapeutics price target on strategy shift By Investing.com - Investing.com Canada
H.C. Wainwright lowers Actuate Therapeutics price target on strategy shift - Investing.com
Activity Recap: Can Actuate Therapeutics Inc scale operations efficiently2026 Price Action Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Published on: 2026-04-09 23:48:44 - baoquankhu1.vn
Aug Levels: Does Actuate Therapeutics Inc have consistent dividend growth2026 Intraday Action & Community Consensus Trade Signals - baoquankhu1.vn
Actuate Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Profit Review: Is Actuate Therapeutics Inc benefiting from innovation trendsWeekly Trade Analysis & Consistent Return Strategy Ideas - baoquankhu1.vn
Will Actuate (ACTU) Stock Beat Expectations | Price at $2.10, Down 15.32%Street Ratings - Newser
Actuate Therapeutics (NASDAQ:ACTU) Raised to Hold at Wall Street Zen - MarketBeat
ACTU Technical Analysis & Stock Price Forecast - Intellectia AI
Actuate Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Mazar Andrew Paul - Moomoo
Aug Setups: Is Actuate Therapeutics Inc stock showing strong momentum2026 Short Interest & Accurate Intraday Trading Signals - baoquankhu1.vn
Actuate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Actuate Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers - Finviz
Aug Levels: Is Actuate Therapeutics Inc benefiting from innovation trends2026 Retail & Safe Entry Point Identification - baoquankhu1.vn
Aug Outlook: Can Actuate Therapeutics Inc scale operations efficiently2026 Selloffs & Entry Point Confirmation Signals - baoquankhu1.vn
Actuate Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | ACTU | US0050831009 - marketscreener.com
Aug Shorts: Can Actuate Therapeutics Inc outperform under higher oil pricesWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Voss Capital LP Boosts Stake in Actuate Therapeutics, Inc. $ACTU - MarketBeat
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - MSN
Actuate Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors - Bitget
Actuate Therapeutics Inc Stock (ACTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):